Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 7/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | F2 | P00734 | 3/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | METTL3 | Q86U44 | 3/20 | 0.33 |
| ▸ | METTL14 | Q9HCE5 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | F3 | P13726 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30765535 | 0.85 | F2 (0.34) | NAMPTF2METTL3METTL14ALDH1A1 | |
| SCHEMBL30765764 | 0.84 | CMA1 (0.40) | NAMPT | |
| SCHEMBL31558503 | 0.84 | KDR (0.33) | NAMPTCYP2C9F2F3 | |
| SCHEMBL30765987 | 0.83 | F2 (0.37) | NAMPTF2F3HDAC6 | |
| SCHEMBL30765795 | 0.83 | POLB (0.40) | NAMPTCYP2C9F3 | |
| SCHEMBL30765604 | 0.82 | AVPR1B (0.34) | NAMPTF2 | |
| SCHEMBL30765579 | 0.82 | F3 (0.39) | F2F3HDAC6 | |
| SCHEMBL30765580 | 0.82 | ELANE (0.39) | ELANEALDH1A1LMNAHDAC6 | |
| SCHEMBL30765494 | 0.82 | F3 (0.34) | F2LMNAF3 | |
| SCHEMBL30765846 | 0.80 | CMA1 (0.38) | ELANELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| CN-119768164-A | Pharmaceutical compounds for treating complement-mediated disorders | 阿雷克森制药公司 | 2025-04-04 | — | — | CN | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |